ContractClinical Trial Agreement Smlouva O Provedení Klinického Hodnocení • July 16th, 2024
CLINICAL TRIAL AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ This CLINICAL TRIAL AGREEMENT(the “Agreement”) becomes valid and effective by the last party to subscribed below (the “Effective Date”), by and between Fakultní nemocnice v Motole, state founded organisation, located at V Úvalu 84, Zip code: 150 06, Prague 5, Czech Republic, Company ID no.: 00064203, represented by(the “Provider of healthcare services or Provider”) and CLOVIS ONCOLOGY, Inc., located at 5500 Flatiron Parkway, Suite 100, Boulder, CO 80301, USA (the “Sponsor“),who is an employee of the Provider of healthcare services and acting as Principal Investigator (“Investigator”) responsible for the Study as defined below. The Provider of healthcare services and the Investigator may be collectively referred to as the “Site”. The place of the Study execution is Oncology Clinic 2. LF UK and Fakultní nemocnice v Motole at Provider of healthcare services. Tato SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ (dále jen„Smlouva“)
ContractClinical Trial Agreement Smlouva O Provedení Klinického Hodnocení • November 14th, 2022
CLINICAL TRIAL AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ This Clinical Trial Agreement (“Agreement”) is made valid as of the last date of signature and effective as of the latest date of a) publication in the Contracts Register, or b) approval by local RA (SUKL), or c) approval by Local/Multicentric Ethics Committee (“Effective Date”), and is made by and among: Tato smlouva o provedení klinického hodnocení (dále jen "Smlouva") se uzavírá ke dni připojení posledního podpisu a nabývá účinnosti k datu poslední z těchto události: a) zveřejnění v Registru smluv nebo b) schválení místním regulačním orgánem (SUKL) nebo c) schválením místní/multicentrickou etickou komisí (dále jen"Datum účinnosti") mezi těmito Smluvními stranami: Labcorp Drug Development Inc.,with registered office at 206 Carnegie Center, Princeton, NJ 08540, USA, (Tax ID No.: 22-3265977), represented by (REDACTED), and its affiliates(hereinafter referred to as “Labcorp”); and Labcorp Drug Development Inc.,se sídlem
ContractClinical Trial Agreement Smlouva O Provedení Klinického Hodnocení • October 2nd, 2017
CLINICAL TRIAL AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHOHODNOCENÍ This Clinical Trial Agreement (the “Agreement”) is effective as of a date it is published in the Register of Contracts according to the Act No. 340/2015 Coll., on Special Conditions of Effectiveness of Certain Contracts, Publishing of Contracts and Register of Contracts (Act on Register of Contracts) (the “Effective Date”) and is entered into by and between Astellas Pharma Europe B.V., located at Sylviusweg 62, 2333 BE Leiden, the Netherlands (“Sponsor”); INC Research, UK Ltd., located at Riverview, The Meadows Business Park, Station Approach, Blackwater, Camberley, Surrey, GU17 9AB, UK (“INC Research”); and Kroměřížská nemocnice a.s., located at Havlickova 660/69, 767 01 Kromeriz, Czech Republic (“Institution”). Sponsor, INC Research and Institution are individually referred to as a “Party” and arecollectively known as the “Parties”. Tato Smlouva o provedení klinického hodnocení (dále jen „Smlouva”) je platná s účinností
ContractClinical Trial Agreement Smlouva O Provedení Klinického Hodnocení • February 14th, 2022
CLINICAL TRIAL AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ This Clinical Trial Agreement (the “Agreement”) ismade by and between Tato smlouva o provedení klinického hodnocení(dále jen "smlouva") se uzavírá mezi PAREXEL International (IRL) Limited (“CRO”), an Irish corporation, with registered offices at 70 Sir John Rogerson's Quay, Dublin 2, Company No: 541507; VAT Registration No: IE 3249971 HH, Ireland, Represented by Authorized Representative:authorized by Authorization from 2nd November 2021and PAREXEL International (IRL) Limited (dále jen "CRO"), se sídlem na adrese 70 Sir John Rogerson's Quay, Dublin 2, IČ: 541507; DIČ: IE 3249971 HH,Irsko, kterou zastupuje zplnomocněný zástupce:, na základězplnomocnění ze dne 2.11.2021a Janssen Research & Development, LLC (“Janssen”) a United States corporation, with registered offices at 920 Route 202 South Raritan, New Jersey 08869, United States of AmericaDatabox: 8jvdhiaand Janssen Research & Development, LLC (dále jen “Janssen”) Spoj
ContractClinical Trial Agreement Smlouva O Provedení Klinického Hodnocení • April 3rd, 2017
CLINICAL TRIAL AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ This CLINICAL TRIALAGREEMENT (the “Agreement”) is effective 14th of March 2017 (the “Effective Date”), by and between Masarykův onkologický ústav, located at Žlutý kopec 7, Postal code: 656 53, Brno, Czech Republic, company ID no.: 00209805, VAT ID no.: CZ00209805, represented by prof. Jan Žaloudík, MD., Ph.D., Director (the “Provider of healthcare services”) and Clovis Oncology, Inc., located at 5500 Flatiron Parkway, Suite 100, Boulder, CO 80301 (the “Sponsor”), andan employee of the Provider of healthcare services acting within the scope of his/her employment, located at Žlutý kopec 7, Postal code: 656 53, Brno, Czech Republic (the “Investigator”). The Provider of healthcare services and the Investigator may be collectively referred to as the “Site.” Sponsor acknowledge that Pharmaceutical Research Associates CZ, s.r.o., located at Praha 7, Jankovcova 1569/2c, Post Code (PSČ): 170 00, Czech Republic, IČ (company ID nu
ContractClinical Trial Agreement Smlouva O Provedení Klinického Hodnocení • January 18th, 2019
CLINICAL TRIAL AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ This Clinical Trial Agreement (the “Agreement”) is between Tato smlouva o provedení klinického hodnocení (dále jen "smlouva") se uzavírámezi PAREXEL International (IRL) Limited an, with registered offices at 70 Sir John Rogerson's Quay, Dublin 2, IrelandRepresented by :Dora Csabai (“CRO”), and Janssen Research & Development, LLC , with registered offices at 920 Route 202 South, Raritan,New Jersey 08869, United States of America (“Janssen”), PAREXEL International (IRL) Limited, společností se sídlem na adrese 70 Sir John Rogerson's Quay,Dublin 2, Irsko, jednající Dora Csabai (dále jen "CRO") a Janssen Research & Development, LLC, společností se sídlem na adrese 920 Route 202 South, Raritan,New Jersey 08869, Spojené státy Americké (dále jen “Janssen”) and Fakultní nemocnice Královské Vinohradywith registered offices at Šrobárova 150/50 , 100 34 Praha 10, Czech republicID No 00064173Tax ID: CZ 00064173 (“Institution”) and
